ISIS Neutron and Muon Source Data Journal

A Surface Chemistry Approach to Microfluidic Capture of T-Cells for On-Body Therapeutic Manufacturing

Abstract: In late 2017, T-cell therapy became the first gene therapy to have been approved by the US FDA and in 2018 approved for use in the UK. From the clinical data presented thus far, it appears these genetically modified T-cells (a specific type of white blood cell) present a CURE for some of the most aggressive forms of cancer (particularly acute Leukaemia in children). The current manufacture of T-cells is undertaken in a laboratory and can take up to 21 days, depending on the quality of the patient's starting cellular material. The long, complex and expensive process poses the risk of contamination and further complications due to patient variations. Here we propose experiments as part of a larger EPSRC-funded project to move this manufacturing process onto the body. Specifically, we will study a new approach to capture T-cells from whole blood embedded in a microfluidic device under flow.

Principal Investigator: Dr Rob Barker
Local Contact: Dr Mario Campana
Experimenter: Miss Alix Blissett
Experimenter: Miss Chloe Marie Skingle
Experimenter: Mr George Tushingham
Experimenter: Miss charlotte Byford

DOI: 10.5286/ISIS.E.RB1920698

ISIS Experiment Number: RB1920698

Publisher: STFC ISIS Neutron and Muon Source

Data format: RAW/Nexus
Select the data format above to find out more about it.

Data Citation

The recommended format for citing this dataset in a research publication is as:
[author], [date], [title], [publisher], [doi]

For Example:
Dr Rob Barker et al; (2019): A Surface Chemistry Approach to Microfluidic Capture of T-Cells for On-Body Therapeutic Manufacturing, STFC ISIS Neutron and Muon Source, https://doi.org/10.5286/ISIS.E.RB1920698

Data is released under the CC-BY-4.0 license.